Real-World Studies
Multi-omic profiling finds actionable targets in advanced melanoma cohort
Lowinus et alnpj Precision Oncology

In a prospective cohort of 98 patients with advanced cutaneous or uveal melanoma evaluated by the Molecular Tumor Board Freiburg (MTB-FR) between 2021 and 2024, comprehensive multi-omic profiling was evaluated to address therapeutic resistance and toxicities associated with standard immune checkpoint and BRAF/MEK kinase inhibitors.
Completed profiling revealed at least one potential actionable target beyond classical BRAF V600 mutations in 83.8% of evaluated cases. The alterations that most frequently guided recommendations included NRAS mutations, atypical BRAF variants, CDK4/6 pathway amplifications, and DNA-damage response (DDR) gene mutations. Based on these findings, the tumor board recommended biomarker-stratified therapies for 68.4% of patients and personalized immunotherapy combinations for 72.4%.
The treatment implementation rate was 33.8% (n = 27); the abstract does not specify the denominator for this rate. Among patients receiving the recommended regimens, the overall disease control rate (DCR) was 42.9% and the overall response rate (ORR) was 10.7%. The findings demonstrate that comprehensive molecular profiling in real-world advanced melanoma identifies actionable alterations for heavily pretreated populations beyond standard care, though prospective, randomized biomarker-driven trials remain essential to validate whether these individualized strategies translate into a reproducible survival benefit.
Key Takeaways
- Multi-omic profiling identified at least one potential actionable target beyond classical BRAF V600 mutations in 83.8% of cases, leading to biomarker-stratified therapy recommendations in 68.4% of patients and personalized immunotherapy combinations in 72.4%.
- The treatment implementation rate was 33.8% (n = 27); implemented regimens achieved an overall disease control rate of 42.9% and an overall response rate of 10.7%.
Read the original sourcenpj Precision Oncology
